TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01484587
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: form=solution for injection, route=subcutaneous use, ascending dosing for 24 weeks
Study: NCT00811499
Drug: ARRY-371797, p38 inhibitor; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple dose, single schedule
Study: NCT00811499
Drug: Placebo; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT01374438
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules given once daily for 90 days
Study: NCT03938259
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: identification of respiratory parameter changes following administration of fentanyl in children with and without OSA
Study: NCT00836693
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet administered orally once a day for 12 weeks.
Study: NCT00006461
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02741063
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intranasal administration of placebo (24 IU)
Study: NCT00811499
Drug: Placebo; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple dose, single schedule
Study: NCT02426359
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01062932
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of matching placebo pill on Days 1, 4, 7, and 10
Study: NCT04106492
Drug: SQ3370
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ3370 consists of 2 components: SQL70, a protodrug-activating biopolymer, and SQP33, a protodrug of Doxorubicin
Study: NCT00886977
Drug: YAM80
Normalized name: Yam80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration, 2 to 6 mg, once a day.
Study: NCT03799198
Drug: Medication for chronic weight management (Rx)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following listed 5 drugs will be administered as prescribed by the study doctor:~1) Orlistat (Xenical® pills, per os \[p.o.; by mouth\]). 2) Lorcaserin or lorcaserin extended-release (Belviq®/Belviq XR® pills, p.o.). 3) Phentermine/topiramate extended-release (Qsymia® pills, p.o.). 4) Naltrexone/bupropion extended-release (Contrave® pills, p.o.). 5) Liraglutide 3.0 mg (Saxenda® injections, subcutaneously \[under the skin\]).
Study: NCT01153932
Drug: GSK2402968
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT01153932
Drug: matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT03859908
Drug: Iodine Povacrylex 7 MG/ML / Isopropyl Alcohol 0.74 ML/ML
Normalized name: iodine povacrylex 7 MG/ML / isopropyl alcohol 0.74 ML/ML [DuraPrep]
Approvals — FDA: no, EMA: no, PMDA: no
Description: As preoperative antiseptic, applied once as suggested by Centers for Disease Control recommendations in surgical asepsis
Study: NCT03859908
Drug: Chlorhexidine Gluconate 20 MG/ML / Isopropyl Alcohol 0.7 ML/ML
Normalized name: chlorhexidine gluconate 20 MG/ML / isopropyl alcohol 0.7 ML/ML [Soluprep]
Approvals — FDA: no, EMA: no, PMDA: no
Description: As preoperative antiseptic, applied once as suggested by Centers for Disease Control recommendations in surgical asepsis
Study: NCT04165850
Drug: Fixed dose combination Ciprofloxacin/Celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose Ciprofloxacin and Celecoxib capsule to be taken thrice daily, total dose 909mg/day
Study: NCT00908362
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants inhale placebo twice daily via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
Study: NCT01481844
Drug: Lansoprazole , Tab Amoxycillin , Tab Clarithromycin ,Tab Tinidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: use of Sequential therapy as second line treatment for eradication H pylori currently Sequential therapy is indicated as first line treatment for H pylori eradication
Study: NCT01481844
Drug: Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: this combination is standard of care as H pylori second line treatment
Study: NCT04529902
Drug: Tumor Necrosis Factor Inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNFi claim is used as the reference group.
Study: NCT00859196
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product and the respective placebo will be applied to previously wounded test areas and the surrounding skin (approx. 3 cm2). After a certain time the second skin biopsy will be taken from the treated test areas. The skin biopsies will be analysed via micro array.
Study: NCT02293694
Drug: Sayana Press
Normalized name: garden cress sprout extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sayana® Press is a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) in a prefilled, auto-disabled injection system called Uniject
Study: NCT04165174
Drug: Terepril monoclonal antibody; Apatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terepril monoclonal antibody,240mg,ivdrip,Q3W Apatinib,250mg,po,QD
Study: NCT04027517
Drug: JTZ-951
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet~* Dose adjustments as maintenance dose is allowed according to the result of Hb level.
Study: NCT02876432
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg Diclofenac sodium was administrated orally every 12 hours for 5 days.
Study: NCT04322526
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet that has no inherent power to produce an effect. In the inert pill condition, participants will receive an oral placebo tablet.
Study: NCT01981408
Drug: [^14C]-LY2801653
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01715493
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysozyme Matching Placebo three times daily for 4 weeks followed by Lysozyme 90 mg three times daily for 4 weeks (plus usual COPD medication)
Study: NCT00002476
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002476
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002476
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01198496
Drug: Losartan, Losartan and HCTZ, Amlodipine , Spironolactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: \<Study drugs and treatment steps\> Step 1: Losartan 50 mg in principle (other ARB is usable) Step 2: Combination drug containing losartan 50 mg and hydrochlorothiazide 12.5 mg Step 3: Combination drug containing losartan 50mg and HCTZ 12.5mg + amlodipine 5 mg Step 4: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 5 mg Step 5: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 10 mg Step 6: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 10 mg + spironolactone 25 mg
Study: NCT03486834
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution administered as a 0.5 mL IM injection
Study: NCT04476797
Drug: GC4711 +SBRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 minute IV Infusion prior to SBRT
Study: NCT04476797
Drug: Placebo +SBRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 minute IV infusion prior to SBRT
Study: NCT03276858
Drug: Placebo Oral Solution
Normalized name: Placebo Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03276858
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03076710
Drug: Opioids delivered through PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV up to 1 mg. morphine every 10 minutes on request and oral opioids up to 2 tablets of Percocet every 4 hours
Study: NCT03076710
Drug: EXPAREL® infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22 gauge / 3.5 needle, into dermal/fascial/muscular/subcutaneous layers and up to 4mg IV morphine every 60 minutes on request and standardized oral opioids on request
Study: NCT06409546
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral gel applied locally on the MRONJ related lesions or post-extraction sockets
Study: NCT03312231
Drug: AS03
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oil-in-water emulsion based adjuvant system.
Study: NCT01047488
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets to imipramine 25 mg, 3 or 1 tablet evening, daily, 5 weeks Placebo capsules to pregabalin 75 mg, 2 capsules daily, daily, 5 weeks
Study: NCT04081103
Drug: Nexagon® (lufepirsen) High Dose Concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nexagon® (lufepirsen) is administered topically in the affected eye three (3) times over 28 days.
Study: NCT04081103
Drug: Nexagon® (lufepirsen) Low Dose Concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nexagon® (lufepirsen) is administered topically in the affected eye three (3) times over 28 days.
Study: NCT04081103
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle is administered topically in the affected eye three (3) times over 28 days.
Study: NCT04081103
Drug: Open-label Nexagon® (lufepirsen)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label Nexagon® (lufepirsen) for participants who do not heal (re-epithelialize) at the end of the 28-day treatment phase.
Study: NCT00683670
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04077099
Drug: REGN5093
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion. There will be a series of dose escalation cohorts followed by an expansion phase.
Study: NCT00204542
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Solaraze® (Diclofenac sodium) 2x/day topical for 3 months
Study: NCT00204542
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Solaraze® (Diclofenac sodium) 2x/day topical for 6 months
Study: NCT00576667
Drug: Placebo (for Rimonabant)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral administration
Study: NCT04504292
Drug: SUPREP Bowel Prep Kit
Normalized name: Suprep Bowel Prep Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel prep prior to colonoscopy
Study: NCT04504292
Drug: Golytely Oral Product
Normalized name: Golytely Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel prep prior to colonoscopy
Study: NCT04672434
Drug: Sym021
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sym021 is a humanized anti-PD-1 antibody.
Study: NCT04672434
Drug: Sym024
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sym024 is an anti-CD73 antibody.
Study: NCT02461173
Drug: Choriomon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL
Study: NCT00772031
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: an inactive substance
Study: NCT01098266
Drug: NGR-hTNF plus Best Investigator's Choice (BIC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.~* Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis~* Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:~  1. Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles~ 2. Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles~ 3. Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)
Study: NCT02319265
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral liquid
Study: NCT00700466
Drug: i.v. beta-blocker infusion (metoprolol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A beta-blocker (metoprolol) will be infused for treatment of hypertension and/or tachycardia prior to induction of anesthesia aiming at decrease of blood pressure and heart rate to normal limits
Study: NCT03542825
Drug: Iron Supplement
Normalized name: Iron supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron Sulphate 150 mg once daily
Study: NCT03542825
Drug: Chelates, Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid chelated iron capsules contain 15 mg
Study: NCT04323124
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will recieve placebo
Study: NCT03320031
Drug: Humalog Mix 75/25
Normalized name: HumaLOG Mix 75/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer subcutaneous premixed insulin twice a day.
Study: NCT02553226
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both arms will initially receive routine treatment with oxytocin according to national guidelines. When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.
Study: NCT03414983
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT03414983
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT02984813
Drug: GlaucoHealth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Containing alpha lipoic acid, citicoline, Co-enzyme Q10, Ginkgo biloba extract, grape seed extract, N-acetyl-cysteine, curcumin, and green tea extract
Study: NCT02984813
Drug: GlaucoSelect
Approvals — FDA: no, EMA: no, PMDA: no
Description: Containing curcumin, bilberry extract, and grape seed extract
Study: NCT02984813
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active ingredients
Study: NCT03390946
Drug: Poor responder group adjuvant chemotherapy
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poor responder group (necrosis ≤ 90%)~: week 0, 7 and 14, doxorubicin; week 2, 9 and 16, ifosfamde, week 4, 11, 18 and 19, methotrexate; wk 5, 12 and 20~B. Resection of tumor~C. Adjuvant chemotherapy~1. Poor responder group (necrosis ≤ 90%)~   * week 0, 7 and 14, doxorubicin; week 2, 9 and 16, ifosfamde, week 4, 11, 18 and 19, methotrexate; wk 5, 12 and 20~2. Good responder group (necrosis \> 90%)~   * week 0 and 8, doxorubicin; week 2 and 10, ifosfamide; week 4, 5, 12 and 13, methotrexate; week 6 and 14, cisplatin
Study: NCT03390946
Drug: Good responder group adjuvant chemotherapy
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Good responder group (necrosis \> 90%)~: week 0 and 8, doxorubicin; week 2 and 10, ifosfamide; week 4, 5, 12 and 13, methotrexate; week 6 and 14, cisplatin
Study: NCT03018652
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL/kg, up to maximum of 800 mL will be given on the day of randomization (this will match the volume of 0.5g/kg of IVIG product) and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks)
Study: NCT02432027
Drug: C-82 Topical Gel, Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02432027
Drug: C-82 Topical Gel, 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: active
Study: NCT01575158
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00967356
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension
Study: NCT01946295
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00535639
Drug: Betula Verrucosa allergen extract
Normalized name: Betula lenta allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01222052
Drug: 5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q3weeks followed by Docetaxel 100 mg/m² q3weeks~Arm B 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q6weeks
Study: NCT00471939
Drug: I-020502
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mcg/mL TG-PDGF.AB
Study: NCT02078557
Drug: MK-8892
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01094821
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule three times daily for 9 days
Study: NCT00912535
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally, as adjunct to the same antidepressant at the same dose.
Study: NCT00003695
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01269138
Drug: recombinant FVIIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of bleeding episodes,treatment during surgery and prophylaxis
Study: NCT01269138
Drug: Fresh Frozen Plasma
Normalized name: Fresh frozen plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of bleeding episodes,treatment during surgery and prophylaxis
Study: NCT01439308
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-705498 placebo
Study: NCT01392105
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment of mesenchymal stem cells
Study: NCT04652245
Drug: Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, one spray in each nostril of Placebo nasal spray at Visit 5
Study: NCT01596010
Drug: 2 mg estradiol / 1 mg norethisterone acetate (NETA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of one tablet under fasting conditions separated by a wash-out period of 2 weeks (+0-2 days) between dosing visits. Administered orally.
Study: NCT03823521
Drug: Cardioplegia Solution
Normalized name: cardioplegia solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardioplexol™ will be adminstered in cardiac surgery as cardioplegic solution
Study: NCT01075529
Drug: fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fluoxetine 20 mg/d
Study: NCT03321773
Drug: triple therapy plus bismuth therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole 40mg twice daily for 14 days, amoxicillin 1g twice daily for 14 days, clarithromycin 500mg twice daily for 14 days, bismuth subcitrate 240mg twice daily for 14 days.
Study: NCT03321773
Drug: reverse hybrid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: (pantoprazole 40mg twice daily for 7 days, amoxicillin 1 g twice dailyfor 7 days, clarithromycin 500 mg twice daily for 7 days, and metronidazole 500 mg twice daily for 7 days) followed by (pantoprazole 40mg twice daily for 7 days and amoxicillin 1 g twice daily for 7 days)
Study: NCT02707562
Drug: GLPG1837 dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for one week
Study: NCT02707562
Drug: GLPG1837 dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for one week
Study: NCT02707562
Drug: GLPG1837 dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for two weeks
Study: NCT03207295
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline(2ml/h) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children
Study: NCT02664935
Drug: AZD4547
Approvals — FDA: no, EMA: no, PMDA: no
Description: FGFR Inhibitor
Study: NCT02664935
Drug: AZD5363
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKT Inhibitor
Study: NCT01959282
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo once daily
Study: NCT01959282
Drug: JNJ-54781532 25 mg once daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 25 mg of JNJ-54781532 once daily
Study: NCT02664935
Drug: AZD6738
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATR inhibitor
Study: NCT01959282
Drug: JNJ-54781532 150 mg once daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 150 mg of JNJ-54781532 once daily
Study: NCT01959282
Drug: JNJ-54781532 75 mg twice daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 75 mg of JNJ-54781532 twice daily
Study: NCT00620191
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo identical to metformin 2 tablets twice a day titrated from one table once a day
Study: NCT01830621
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04435652
Drug: QL1604
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mg/kg, D1,8,15,Q4w, IV infusion
Study: NCT00264186
Drug: LPS 2 ng/kg intravenous (IV) bolus
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00264186
Drug: rhSOD 82,000 IU (8.2 mg)/min intraarterially
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00264186
Drug: Norepinephrine 60, 120, 240 pmol/min intraarterially over 5 min/dose level (two times; pre-dose and +3.5 hrs)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00264186
Drug: Acetylcholine 6.25, 12.5, 25 nmol/min intraarterially over 3 min/dose level (two times; pre-dose and +3.5 hrs)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00907335
Drug: Retin-A Micro 0.04% facial acne treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retin-A Micro 0.04% facial acne treatment used once daily
Study: NCT02631239
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1g/m2/d IV \*1d
Study: NCT00976989
Drug: FEC
Normalized name: Fectrim
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil 500 mg/m\^2, epirubicin 100 mg/m\^2 and cyclophosphamide 600 mg/m\^2.
Study: NCT05021978
Drug: Part A: 20 and 40 mg PRAX-944
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral treatment